title: Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in advanced gastric cancers.
abstract: Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 114 advanced gastric cancers and correlated with clinical behavior. DNA diploidy was observed in 45 (39.5%) and aneuploidy in 69 (60.5%) cases. By setting the cutoff line at the level used in a negative control study without primary antibody in the same sample, the p105-labeling rate was calculated by the p105-DNA dual fluorescence analysis. The mean p105-labeling rate was 37.7% (range, 9.3% to 79.0%). The p105-labeling rates were significantly higher (P less than 0.05) for aneuploid DNA, liver metastasis, vascular invasion, and histologically well-differentiated tumors. The 5-year survival rate of patients with high p105-labeling tumors (p105-labeling rate, greater than 30%) was significantly poorer (P less than 0.01) than that of patients with low-labeling tumors. When the p105-labeling rate and the clinicopathologic parameters were entered simultaneously into the Cox regression model, the stage of disease, DNA ploidy, p105-labeling rate, and vascular invasion emerged as independent prognostic parameters. These findings indicate that the measurement of p105 may provide useful information for predicting prognosis in advanced gastric cancers.
authors.affiliation: Department of Surgery II, School of Medicine, Kanazawa University, Ishikawa, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kimura
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: A L
authors.initials: AL
authors.lastname: Epstein
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis*; D034961:Antigens, Nuclear; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000032:analysis*; D011003:Ploidies; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000235:genetics* / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis
chemical_list: D000951:Antigens, Neoplasm; D034961:Antigens, Nuclear; D004273:DNA, Neoplasm; D009687:Nuclear Proteins